Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health is expected to have a positive outlook as their RAPID pathway aims to expedite the approval process for their lead product candidate, Revita. With funds to sustain operations until early 2027 and strong results expected in the fourth quarter of 2026, recent studies have shown Revita's potential to effectively maintain weight loss. Despite facing standard risks in the industry, Fractyl Health's data supports the potential success of Revita as a one-time treatment option for weight control.

Bears say

Fractyl Health is facing significant challenges in its goal of treating obesity and type 2 diabetes, as its lead product candidate Revita has not shown strong enough weight loss results and has minimal effect on HbA1c levels. This could limit the company's potential for adoption and commercial success, especially considering the small sample size and relatively short follow-up period in clinical trials. Additionally, the company's potential De Novo reclassification in 2026 and pivotal cohort data in 4Q26 may not be enough to offset these challenges and justify a positive outlook on the stock.

GUTS has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.